FDA Issues Two Federal Register Notices on Prescription Drug Promotion
On December 11, 2017, the United States Food and Drug Administration (FDA) published two Federal Register notices regarding prescription drug promotion from the FDA’s Center for Drug Evaluation and Research (CDER) Office of Prescription Drug Promotion (OPDP).
Final Guidance on Promotional Labeling
The first notice announces the FDA’s Final Guidance on product name placement, size, prominence, and frequency in promotional labeling and advertisement for prescription drugs (human and animal), including prescription biological products. The FDA believes that the disclosure of the product name in promotional materials is important for the proper identification of the products to help ensure they are used safely and effectively.
The recommendations in this guidance relate to product names in traditional print media promotional labeling and advertisements such as journal ads, detail aids, brochures; audiovisual promotional labeling, such as videos shown in a health care provider’s office; broadcast advertisements (e.g., television advertisements, radio advertisements); and electronic and computer-based promotions such as internet, social media, emails, CD-ROMs, DVDs). In this guidance, FDA further clarifies issues relating to the direct conjunction of the proprietary and established names, as well as the frequency of use of the established name on printed pages or spreads, in running text or columns, in the audio portion of audiovisual promotions, and in electronic media.
...
Source: Policy and Medicine - Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
More News: Advertising | American Health | Chronic Pain | Computers | Eating Disorders & Weight Management | Emergency Medicine | Food and Drug Administration (FDA) | Health Management | HIV AIDS | Internal Medicine | International Medicine & Public Health | Internet | Obesity | Pain | Primary Care | Study | USA Health | Websites